Logo image of ONC

BEONE MEDICINES LTD-ADR (ONC) Stock Fundamental Analysis

USA - NASDAQ:ONC - US07725L1026 - ADR

343.87 USD
-1.3 (-0.38%)
Last: 10/3/2025, 8:00:02 PM
343.87 USD
0 (0%)
After Hours: 10/3/2025, 8:00:02 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ONC. ONC was compared to 536 industry peers in the Biotechnology industry. The financial health of ONC is average, but there are quite some concerns on its profitability. ONC is evaluated to be cheap and growing strongly. This does not happen too often!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ONC had positive earnings in the past year.
ONC had a positive operating cash flow in the past year.
In the past 5 years ONC always reported negative net income.
In the past 5 years ONC always reported negative operating cash flow.
ONC Yearly Net Income VS EBIT VS OCF VS FCFONC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -2B -4B -6B -8B -10B

1.2 Ratios

ONC has a better Return On Assets (-3.68%) than 87.87% of its industry peers.
ONC has a better Return On Equity (-6.15%) than 89.74% of its industry peers.
Industry RankSector Rank
ROA -3.68%
ROE -6.15%
ROIC N/A
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ONC Yearly ROA, ROE, ROICONC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of ONC (85.37%) is better than 88.25% of its industry peers.
In the last couple of years the Gross Margin of ONC has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ONC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
ONC Yearly Profit, Operating, Gross MarginsONC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

5

2. Health

2.1 Basic Checks

ONC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ONC has been increased compared to 1 year ago.
Compared to 5 years ago, ONC has more shares outstanding
Compared to 1 year ago, ONC has a worse debt to assets ratio.
ONC Yearly Shares OutstandingONC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ONC Yearly Total Debt VS Total AssetsONC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.2 Solvency

An Altman-Z score of 8.86 indicates that ONC is not in any danger for bankruptcy at the moment.
ONC has a better Altman-Z score (8.86) than 82.84% of its industry peers.
ONC has a debt to FCF ratio of 5.47. This is a neutral value as ONC would need 5.47 years to pay back of all of its debts.
ONC's Debt to FCF ratio of 5.47 is amongst the best of the industry. ONC outperforms 92.35% of its industry peers.
ONC has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ONC (0.26) is worse than 69.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.47
Altman-Z 8.86
ROIC/WACCN/A
WACC4.86%
ONC Yearly LT Debt VS Equity VS FCFONC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B 30B

2.3 Liquidity

A Current Ratio of 1.94 indicates that ONC should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.94, ONC is doing worse than 76.31% of the companies in the same industry.
ONC has a Quick Ratio of 1.71. This is a normal value and indicates that ONC is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ONC (1.71) is worse than 78.17% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.71
ONC Yearly Current Assets VS Current LiabilitesONC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 217.74% over the past year.
Looking at the last year, ONC shows a very strong growth in Revenue. The Revenue has grown by 47.67%.
ONC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.91% yearly.
EPS 1Y (TTM)217.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.68%
Revenue 1Y (TTM)47.67%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.76%

3.2 Future

Based on estimates for the next years, ONC will show a very strong growth in Earnings Per Share. The EPS will grow by 94.51% on average per year.
Based on estimates for the next years, ONC will show a quite strong growth in Revenue. The Revenue will grow by 18.90% on average per year.
EPS Next Y121.46%
EPS Next 2Y65.99%
EPS Next 3Y48.32%
EPS Next 5Y94.51%
Revenue Next Year41.54%
Revenue Next 2Y30.11%
Revenue Next 3Y24%
Revenue Next 5Y18.9%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ONC Yearly Revenue VS EstimatesONC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20B 40B 60B
ONC Yearly EPS VS EstimatesONC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 500 1K 1.5K 2K

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 6.01, which indicates a rather cheap valuation of ONC.
ONC's Price/Earnings ratio is rather cheap when compared to the industry. ONC is cheaper than 97.76% of the companies in the same industry.
When comparing the Price/Earnings ratio of ONC to the average of the S&P500 Index (27.86), we can say ONC is valued rather cheaply.
The Price/Forward Earnings ratio is 68.23, which means the current valuation is very expensive for ONC.
ONC's Price/Forward Earnings ratio is rather cheap when compared to the industry. ONC is cheaper than 88.06% of the companies in the same industry.
ONC is valuated expensively when we compare the Price/Forward Earnings ratio to 23.32, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 6.01
Fwd PE 68.23
ONC Price Earnings VS Forward Price EarningsONC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

91.23% of the companies in the same industry are more expensive than ONC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 216.53
EV/EBITDA N/A
ONC Per share dataONC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

ONC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ONC's earnings are expected to grow with 48.32% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y65.99%
EPS Next 3Y48.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ONC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEONE MEDICINES LTD-ADR

NASDAQ:ONC (10/3/2025, 8:00:02 PM)

After market: 343.87 0 (0%)

343.87

-1.3 (-0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/dmh
Earnings (Next)11-12 2025-11-12
Inst Owners33.86%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change5.81%
Market Cap37.77B
Analysts81.43
Price Target336.73 (-2.08%)
Short Float %18.4%
Short Ratio4.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.55
Dividend Growth(5Y)N/A
DP-30.61%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2148.49%
Min EPS beat(2)1187.13%
Max EPS beat(2)3109.85%
EPS beat(4)3
Avg EPS beat(4)1518.68%
Min EPS beat(4)-22.81%
Max EPS beat(4)3109.85%
EPS beat(8)4
Avg EPS beat(8)536.4%
EPS beat(12)5
Avg EPS beat(12)344.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.52%
Min Revenue beat(2)-1.25%
Max Revenue beat(2)6.29%
Revenue beat(4)3
Avg Revenue beat(4)2.7%
Min Revenue beat(4)-1.25%
Max Revenue beat(4)6.29%
Revenue beat(8)7
Avg Revenue beat(8)13.13%
Revenue beat(12)11
Avg Revenue beat(12)13.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.48%
PT rev (3m)30.87%
EPS NQ rev (1m)14.94%
EPS NQ rev (3m)N/A
EPS NY rev (1m)14.94%
EPS NY rev (3m)135.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.18%
Revenue NY rev (3m)2.85%
Valuation
Industry RankSector Rank
PE 6.01
Fwd PE 68.23
P/S 8.89
P/FCF 216.53
P/OCF 83.75
P/B 10.84
P/tB 11.36
EV/EBITDA N/A
EPS(TTM)57.23
EY16.64%
EPS(NY)5.04
Fwd EY1.47%
FCF(TTM)1.59
FCFY0.46%
OCF(TTM)4.11
OCFY1.19%
SpS38.68
BVpS31.73
TBVpS30.26
PEG (NY)0.05
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.68%
ROE -6.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.37%
FCFM 4.11%
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
F-Score6
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.47
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 6.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.71
Altman-Z 8.86
F-Score6
WACC4.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)20.18%
Cap/Sales(5y)27.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)217.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.68%
EPS Next Y121.46%
EPS Next 2Y65.99%
EPS Next 3Y48.32%
EPS Next 5Y94.51%
Revenue 1Y (TTM)47.67%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.76%
Revenue Next Year41.54%
Revenue Next 2Y30.11%
Revenue Next 3Y24%
Revenue Next 5Y18.9%
EBIT growth 1Y89.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year146.94%
EBIT Next 3Y63.92%
EBIT Next 5Y55.36%
FCF growth 1Y110.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y136.32%
OCF growth 3YN/A
OCF growth 5YN/A